Literature DB >> 32133504

Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome.

Brandon P Galm1, Nidan Qiao1,2, Anne Klibanski1, Beverly M K Biller1, Nicholas A Tritos1.   

Abstract

CONTEXT: The diagnosis of Cushing syndrome (CS) can be challenging. It remains to be determined which diagnostic tests are the most accurate.
OBJECTIVE: To summarize the accuracy of diagnostic tests for CS using contemporary meta-analytic techniques (hierarchical models). DATA SOURCES: PubMed, Embase, Scopus, Web of Science, and the Cochrane Database of Systemic Reviews (inception until August 3, 2018). STUDY SELECTION: Studies performed in adults that determined the accuracy of one or more diagnostic tests: overnight 1-mg dexamethasone suppression test (DST), 2-day low-dose DST (2d DST), 24-hour urinary free cortisol (UFC), late-night salivary cortisol (LNSC), midnight serum cortisol (MSC), and the dexamethasone-suppressed CRH (dex-CRH) and desmopressin (dex-DDAVP) tests. DATA EXTRACTION: Two authors independently extracted data and performed methodological assessments. DATA SYNTHESIS: One hundred thirty-nine studies (14 140 participants) were included in the analysis. The respective sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio (95% confidence interval [CI]) estimates include the following: DST 98.6% (96.9%-99.4%), 90.6% (86.4%-93.6%), 10.5 (7.2-15.3), and 0.016 (0.007-0.035); 2d DST 95.3% (91.3%-97.5%), 92.8% (85.7%-96.5%), 13.2 (6.47-27.1), and 0.051 (0.027-0.095); UFC 94.0% (91.6%-95.7%), 93.0% (89.0%-95.5%), 13.3 (8.47-21.0), and 0.065 (0.046-0.092); LNSC 95.8% (93.%-97.2%), 93.4% (90.7%-95.4%), 14.6 (10.3-20.7), and 0.045 (0.030-0.066); MSC 96.1% (93.5%-97.6%), 93.2% (88.1%-96.3%), 14.2 (7.96-25.2), and 0.042 (0.026-0.069); and dex-CRH 98.6% (90.4%-99.8%), 85.9% (67.6%-94.7%), 7.0 (2.80-17.6), and 0.016 (0.002-0.118). A single study evaluated dex-DDAVP. Meta-regression and a novel network meta-analytic approach suggest that DST is the most sensitive while UFC is the least sensitive.
CONCLUSIONS: All of the included diagnostic tests for CS are highly sensitive and specific. It appears that the DST is the most sensitive while the UFC is less sensitive. The specificity of all first-line tests appears comparable. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cushing syndrome; dexamethasone suppression test; dexamethasone-suppressed CRH test; late-night salivary cortisol; midnight serum cortisol; urinary free cortisol or urine free cortisol

Mesh:

Substances:

Year:  2020        PMID: 32133504     DOI: 10.1210/clinem/dgaa105

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

2.  Pituitary tumor centers of excellence for Cushing's disease.

Authors:  Marcos Couselo; Stefano Frara; Andrea Giustina; Felipe F Casanueva
Journal:  Pituitary       Date:  2022-09-10       Impact factor: 3.599

Review 3.  Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing's Syndrome.

Authors:  Lynnette K Nieman
Journal:  Endocr Rev       Date:  2022-09-26       Impact factor: 25.261

4.  Coexistence of Cushing Disease With a Solitary Adrenocorticotrophic Hormone-Dependent Adrenal Adenoma.

Authors:  Mohamed K M Shakir; Ismail C Ebrahim; Andrew Spiro; Vinh Q Mai; Thanh D Hoang
Journal:  AACE Clin Case Rep       Date:  2020-12-08

5.  A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score.

Authors:  Mirko Parasiliti-Caprino; Fabio Bioletto; Tommaso Frigerio; Valentina D'Angelo; Filippo Ceccato; Francesco Ferraù; Rosario Ferrigno; Marianna Minnetti; Carla Scaroni; Salvatore Cannavò; Rosario Pivonello; Andrea Isidori; Fabio Broglio; Roberta Giordano; Maurizio Spinello; Silvia Grottoli; Emanuela Arvat
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-05       Impact factor: 5.555

6.  Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling.

Authors:  Adina F Turcu; Richard Auchus
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

7.  Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome.

Authors:  Joshua Kannankeril; Ty Carroll; James W Findling; Bradley Javorsky; Ian L Gunsolus; Jonathan Phillips; Hershel Raff
Journal:  J Endocr Soc       Date:  2020-07-24

8.  Two-day low-dose dexamethasone suppression test more accurate than overnight 1-mg in women taking oral contraceptives.

Authors:  Tiphaine Carton; Elise Mathieu; Fleur Wolff; Jason Bouziotis; Bernard Corvilain; Natacha Driessens
Journal:  Endocrinol Diabetes Metab       Date:  2021-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.